普罗塔疫苗2.0通过降解多种病毒蛋白来产生流感疫苗
Chunhe Zhang1, Jihuan Hou1, Zhen Li1
1State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Nature chemical biology
|January 15, 2025
概括
下一代蛋白质溶解向 (PROTAR) 疫苗 (PROTAR 2.0) 利用无素-蛋白酶系统 (UPS) 来制造高度减弱的流感疫苗. 普罗塔 2.0 诱导广泛的,交叉保护性免疫与单一剂量.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 分子生物学分子生物学
背景情况:
- 细胞无素-蛋白酶体系统 (UPS) 是活衰减疫苗开发的目标.
- 第一代蛋白质分解向 (PROTAR) 疫苗由于终端蛋白质修饰而存在局限性.
- 通过UPS准病毒蛋白稳定性提供了一个新的疫苗策略.
研究的目的:
- 为流感病毒开发一个改进的PROTAR疫苗平台 (PROTAR 2.0) .
- 为了在各种基因组位置灵活地纳入蛋白质酶向降解基因 (PTDs).
- 评估PROTAR 2.0流感疫苗的疗效和免疫性.
主要方法:
- 在内部和终端基因组位点集成PTD的工程流感病毒.
- 在UPS缺少细胞中培养的病毒用于放大,在常规细胞中用于减弱.
- 在动物模型中进行单剂量鼻内免疫接种.
主要成果:
- PROTAR 2.0病毒在缺乏UPS的细胞中有效复制,但通过PTD介导的降解在常规细胞中减弱.
- 有多个PTD的优化PROTAR 2.0候选人表现出高衰减.
- 单剂量内鼻接种引发了强大的,广泛的免疫反应和完全的交叉保护性免疫力.
结论:
- PROTAR 2.0 代表了活体减弱型流感疫苗的多功能和有效平台.
- 灵活的PTD结合增强了疫苗的潜力和广泛的免疫性.
- 在控制流感感染方面,PROTAR 2.0疫苗提供了显著的优势.
相关概念视频
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:51Vaccinations
44.2K
Overview
44.2K
00:57Viral Recombination
23.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.3K